Competitors ahead of us have failed with the TSS and that's what the FDA hold in the highest regard.
Safety profile paramount in this patient population. You can see why Hashan thinks in the long run, SNT-5505 could potentially be part of the standard of care in the early patient population = big $$$
SNT Price at posting:
6.7¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)